Top marks for Cherwell’s Redipor prepared microbial media products
Extensive range of ready-to-use culture media available in bottles and plates.
A recent customer satisfaction survey has affirmed that the vast majority would recommend Cherwell and its Redipor microbiological media products to a colleague. Value for money, excellent customer service and product quality were all key factors contributing to the very positive outcome of this survey. These results are evidenced by Redipor’s growing user base within the pharmaceutical and associated industries both domestically and across Europe. Therefore, to accommodate all customers, Cherwell has just released both UK and Euro versions of its 2018/19 Redipor Prepared Media price list, now available to download from Cherwell’s website.
Redipor prepared media products scored highly with customers in Cherwell’s recent survey to achieve an impressive Net Promoter Score of +76 (from a range of -100 to +100). Customer comments as to ‘Why Cherwell?’ included: ”The excellent service; great pricing; exceeding expectations with delivery times; helping us out in a crisis; flexibility by preparing bespoke media; pragmatic advice; and realistic timeframes. What more could anyone want?”
Meeting varying customer needs, such as for environmental monitoring, sterility testing and validation applications, the new Redipor price list details the extensive range of ready-to-use culture media available in bottles and plates. Cherwell provides a selection of the most commonly requested types, many of which are available from stock for next day delivery. In addition to those included in the price list, Cherwell offers many other bespoke products which are made to order with short lead times and small minimum order requirements. Discounts are available for high volume and standing orders.
“With customer satisfaction and ease of access in mind, we have laid out our new Redipor price list to enable straightforward reference of ordering information and products,” said Andrew Ramage, Cherwell’s Microbiology Product Specialist. “And if customers can't find exactly what they need, we’d like to hear from them as we frequently adapt to meet specific requirements, be it the media formulation, format, packaging or quantity. We are also very happy to provide rapid quotations and flexible delivery schedules.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance